A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl4) Exposure Through an Orogastric Tube

11.4K views

DOI:

10.3791/60695

April 28th, 2020

* These authors contributed equally

In This Article

Summary

This protocol describes a common and feasible method of inducing acute liver injury (ALI) via CCl4 exposure through an orogastric tube. CCl4 exposure induces ALI through the formation of reactive oxygen species during its biotransformation in the liver. This method is used to analyze the pathophysiology of ALI and examine different hepatoprotective strategies.

Abstract

Acute liver injury (ALI) plays a crucial role in the development of hepatic failure, which is characterized by severe liver dysfunction including complications such as hepatic encephalopathy and impaired protein synthesis. Appropriate animal models are vital to test the mechanism and pathophysiology of ALI and investigate different hepatoprotective strategies. Due to its ability to perform chemical transformations, carbon tetrachloride (CCl4) is widely used in the liver to induce ALI through the formation of reactive oxygen species. CCl4 exposure can be performed intraperitoneally, by inhalation, or through a nasogastric or orogastric tube. Here, we describe a rodent model, in which ALI is induced by CCl4 exposure through an orogastric tube. This method is inexpensive, easily performed, and has minimal hazard risk. The model is highly reproducible and can be widely used to determine the efficacy of potential hepatoprotective strategies and assess markers of liver injury.

Introduction

The frequency of toxic insults to the liver, especially due to alcohol and drug abuse, is increasing. Acute liver injury (ALI) is associated with high mortality rates and has caused clinical concerns1,2. Toxic injury leads to death signaling pathways in the liver, resulting in hepatocyte apoptosis, necrosis, or pyroptosis. ALI plays a crucial role in the development of hepatic failure, which is characterized by severe liver dysfunction including complications such as hepatic encephalopathy and impaired protein synthesis3,4. Although recent research has....

Access restricted. Please log in or start a trial to view this content.

Protocol

The experiments were conducted according to the recommendations of the Declarations of Helsinki and Tokyo and to the Guidelines for the Use of Experimental Animals of the European Community. The experiments were approved by the Animal Care Committee of Ben-Gurion University of the Negev.

NOTE: The CCl4 model has been generated and used in a previous study17. The protocol timeline is demonstrated in Table 1.

1. Preparing rats for the experimental procedure

NOTE: Select adult male Sprague Dawley rats weighing 300−350 g.

Access restricted. Please log in or start a trial to view this content.

Results

The TB, GOT, and GPT levels significantly increased 24 h after inducing ALI (more at higher CCl4 doses) compared to sham-operated controls (p < 0.001) (Figure 1). The levels of TB, GOT, and GPT at baseline were normal and were not significantly different than sham-operated controls. At 24 h, all three interventional groups, 1 mL/kg CCl4 (1, 1−2), 2.5 mL/kg CCl4 (3, 3−4), and 5 mL/kg CCl4 (4, 4−5.75), had a significantly higher histological gradi.......

Access restricted. Please log in or start a trial to view this content.

Discussion

In this protocol, CCl4 is used as a liver toxin to induce ALI in rats. ALI is characterized by loss of hepatic parenchyma and subsequent dysregulation of the liver’s metabolic and synthetic functions. Drugs, viruses, toxins, autoimmune diseases, metabolic diseases, and vascular disorders all induce hepatocyte death, and the subsequent inflammatory response contributes to the pathogenesis of ALI.

The initial insult to the liver leads to cytokine production, chemokine release, a.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have nothing to disclose.

Acknowledgements

The authors gratefully acknowledge Bertha Delgado, Department of Pathology, Soroka Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, for her help in the laboratory as well as in the histology analysis.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
22 G catheter BD Neoflon TMBecton Dickinson Infusion Therapy AB
4% buffered formaldehyde solutionSigma - Aldrich lab materials technologies
BD Microtainer SST TM TubesBecton Dickinson and Company
Carbone tetrachlorideSigma - Aldrich lab materials technologiesCAS 56-23-5
Isofluran, USP 100%Piramamal Critical Care, Inc
Olympus AU2700 Chemistry-Immuno AnalyzerOlympus (MN, USA)Analysis of blood samples was done by the fluorescence method
Olympus BX 40 microscopeOlympus
RAT Feeding NeedlesORCHID SCIENTIFICS
SYRINGE SET 1 and 2 ml MEDI -PLUSShandong Zibo Shanchuan Medical Instruments Co., Ltd

References

  1. Hoofnagle, J. H., Carithers, R. L., Shapiro, C., Ascher, N. Fulminant hepatic failure: Summary of a workshop. Hepatology. 21 (1), 240-252 (1995).
  2. Rakela, J., Lange, S. M., Ludwig, J., Baldus, W. P. Fulminant hepatitis: Mayo clinic experience with 34 cases. Mayo Clinic Proceedings.

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Tags

Sprague Dawley RatsSerum GOT GPTTotal BilirubinHistopathological GradingHematoxylin Eosin StainingHepatoprotective StrategiesLiver Enzyme Analysis